Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gnant, M; Dubsky, P; Fitzal, F; Blaha, P; Schoppmann, S; Steger, G; Marth, C; Samonigg, H; Hüttner, K; Fohler, H; Ruecklinger, E; Jakesz, R; Greil, R; Austrian Breast and Colorectal Cancer Study Group.
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Clin Breast Cancer. 2009; 9 Suppl 1: S18-S27. Doi: 10.3816/CBC.2009.s.002
Web of Science PubMed FullText FullText_MUG Google Scholar


Co-Autor*innen der Med Uni Graz
Samonigg Hellmut
Study Group Mitglieder der Med Uni Graz:
Hofmann Guenter

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Women undergoing treatment for breast cancer often experience a marked decrease in bone mineral density. This decrease is observed with chemotherapy as well as endocrine therapy and is more pronounced and rapid than normal postmenopausal bone loss. Pharmacologic intervention is, therefore, necessary in many cases to preserve bone health and prevent fractures. Many small studies have demonstrated that cancer therapy-induced bone loss (CTIBL) is effectively prevented by bone-targeted therapies, such as bisphosphonates and other inhibitors of bone resorption. Recently, several trials have confirmed the efficacy of bisphosphonates in the prevention of CTIBL in both premenopausal and postmenopausal women with early-stage breast cancer. In addition, concomitant treatment with zoledronic acid 4 mg every 6 months and standard adjuvant endocrine therapy has been reported to significantly improve disease-free survival and decrease disease recurrence in bone as well as other sites compared with standard therapy alone. Zoledronic acid treatment has also decreased residual tumor volume in the neoadjuvant setting. Furthermore, long-term follow-up of a single study in patients with bone marrow micrometastases from breast cancer revealed overall survival benefits for patients receiving clodronate 1600 mg/day compared with placebo; however, combined results from several trials of clodronate are inconclusive. Overall, a large body of evidence is accumulating to support the potential adjuvant benefits of bisphosphonates in the treatment of early-stage breast cancer. Results from ongoing studies are expected to further elucidate the benefits of bisphosphonates in maintaining bone health and improving clinical outcomes in patients with breast cancer.
Find related publications in this database (using NLM MeSH Indexing)
Adjuvants, Pharmaceutic - therapeutic use
Antineoplastic Agents - adverse effects
Bone Density - drug effects
Bone Density Conservation Agents - therapeutic use
Bone Diseases, Metabolic - chemically induced Bone Diseases, Metabolic - drug therapy Bone Diseases, Metabolic - physiopathology
Breast Neoplasms - physiopathology Breast Neoplasms - therapy
Clinical Trials as Topic -
Diphosphonates - therapeutic use
Female -
Humans -

Find related publications in this database (Keywords)
Bone loss
Disease recurrence
Endocrine therapy
Zoledronic acid
© Med Uni Graz Impressum